fbpx
    • Multiple Myeloma News
    • Nov 01, 2019

    Lenalidomide Can Delay Bone and Organ Damage for Smoldering Myeloma Patients

image_print

In the largest ever study of smoldering myeloma patients from 13 major myeloma facilities, lenalidomide was found to delay disease progression, and helped prevent bone damage and end organ damage. The study was run by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.

 
“Curative” treatment strategies are also being evaluated for high risk smoldering myeloma patients. Such a study is the ECOG-ACRIN study, comparing daratumumab, lenalidomide, and dexamethasone (with the goal of a cure) vs. lenalidomide plus dexamethasone (with the goal of prevention). The future results from this study can be compared to this current study and will provide clarity on the best long-term strategy for high risk smoldering myeloma. While we are waiting on those results, lead study author Vincent Rajkumar, MD of the Mayo Clinic said:

 

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

Leave A Comment

Please enter the correct captcha code to verify that you are human.

MYELOMA CROWD RESEARCH INITIATIVE
$167301 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: